Compare Neurocrine Biosciences Inc (NBIX) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Upwork Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.7 (market cap $14.36B), while Upwork Inc trades at $8.64 (market cap $1.07B). The key difference: Neurocrine Biosciences Inc is far larger — about 13.4× Upwork Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Upwork Inc for 38 Days on average.
| NBIX | UPWK | |
|---|---|---|
Market Cap | $14.36B | $1.07B |
Volume | 1,237,180 | 2,574,130 |
Sector | Health | Industrials |
52-Week High | $185.50 | $22.11 |
52-Week Low | $123.10 | $7.84 |
Typical Hold Time | 23 Days | 38 Days |
Enterprise Value | $14.37B | $833.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Upwork (UPWK) trades at $8.62, up 2.62% today, with a bearish technical signal despite recent earnings beat. The company maintains strong profitability with 77.21% gross margins and 12.93% net income margin, though revenue growth has stalled at $787M for 2026. Recent insider selling and securities fraud investigations create headwinds, while analyst consensus remains positive with a $9.64 price target.
The stock presents a mixed outlook with attractive valuation metrics (P/E 10.99, P/S 1.48) offset by AI-driven competitive threats and declining active clients. Near-term resistance at $9 and support at $8 will be critical, with institutional accumulation by Bank of America providing some stability amid management selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
